Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Spring Medical, indicating a slight decline in stock price and notable financing activities on February 9 [1] - On February 9, Spring Medical's stock price fell by 0.35%, with a trading volume of 34.99 million yuan. The financing buy-in amounted to 5.24 million yuan, while the financing repayment was 3.77 million yuan, resulting in a net financing buy of 1.48 million yuan [1] - As of February 9, the total financing and securities lending balance for Spring Medical reached 48.55 million yuan, with the financing balance accounting for 0.73% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. Its products are exported to various regions, including Asia, South America, Africa, Oceania, and Europe [2] - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Group 3 - Since its A-share listing, Spring Medical has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Among the top ten circulating shareholders, new entrants include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed A, holding 2.96 million shares and 2.83 million shares, respectively [3]

Group 1 - The Hong Kong stock market saw a strong performance in innovative pharmaceutical stocks, with CSPC Pharmaceutical Group rising over 7%, Kelun-Bio increasing more than 6%, and Innovent Biologics up over 5% [1] - The related ETFs for innovative pharmaceuticals in Hong Kong experienced gains of over 3% [1] Group 2 - Multiple investment opportunities are present in the current healthcare sector, driven by the recovery of overseas orders and domestic capacity clearance in the CXO industry, leading to sustained improvement in market conditions and potential for valuation recovery [2] - The medical device sector benefits from domestic equipment upgrade policies and expansion into overseas markets, with continuous catalysts in cutting-edge areas such as brain-computer interfaces and AI imaging [2] - Internet healthcare is seeing improved operational efficiency and clearer profit growth trajectories amid deepening reforms in medical insurance payment systems [2]

Investment Rating - The report maintains an "Overweight" rating for the medical device industry [2][6]. Core Insights - The medical device procurement scale is experiencing a partial decline due to high base effects, but there are opportunities in the surgical robot market [2]. - The report emphasizes that the ongoing implementation of equipment upgrade policies is expected to drive long-term procurement levels in the medical device sector, recommending companies that are likely to benefit from these policies [4]. - The report highlights that the four ministries jointly issued a notice in 2024 aiming for a more than 25% increase in medical equipment investment by 2027 compared to 2023, which is expected to enhance the configuration of high-end equipment to levels comparable to middle-income countries [6]. Summary by Sections Investment Recommendations - The report suggests maintaining an "Overweight" rating and recommends companies likely to benefit from the equipment upgrade policies, including Mindray Medical, United Imaging, Kaili Medical, Aohua Endoscopy, and Jingfeng Medical-B. It also suggests paying attention to MicroPort Scientific-B [6]. Monthly Procurement Data - In January 2026, the procurement scale for new devices showed a year-on-year decline: MR down 22.6%, CT down 25.6%, DR down 18.2%, ultrasound down 10.1%, while endoscopy grew by 1.1%, and surgical robots declined by 20.1%. Company-specific performance showed United Imaging MR down 36.5%, United Imaging CT up 8.5%, Mindray ultrasound up 10.9%, Kaili ultrasound down 14.8%, Kaili endoscopy up 55.4%, and Aohua endoscopy down 11.7% [6]. Policy Impact - The report discusses the release of a guideline by the National Healthcare Security Administration on January 20, 2026, which establishes a unified pricing project for surgical robots, expected to accelerate the penetration and application of robotic surgery technology [6].

Market Performance - The new stock index and the near-term new stock index fell by 2.01% and 2.23% respectively during the first week of February 2026[7] - The market experienced significant adjustments, with the technology sector leading the decline, particularly in the non-ferrous metals and electronic sectors[7] New Stock Listings - The first unprofitable new stock of the year, Beixin Life, was listed, achieving an average first-day increase of 185.65%[1] - Two new stocks contributed to A1/A2/B class investors' single-account full returns of 17.80/9.44/7.90 thousand yuan, enhancing the yield rates for 500 million scale accounts by 0.36‰/0.19‰/0.16‰[41] Trading Activity - Trading activity in the new stock sector continued to decline, with turnover rates for the new stock index and near-term new stock index dropping by 2.10 percentage points and 2.25 percentage points respectively[21] - The net active selling in the new stock sector was 2.936 billion yuan, a decrease of 3.540 billion yuan from the previous week[23] Valuation Changes - The new stock index PE (TTM) increased by 1.76, while the near-term new stock index PE (TTM) decreased by 23.73[14] - The latest PE (TTM) values for the new stock index and near-term new stock index were 80.0X and 159.7X, corresponding to historical percentile levels of 83.8% and 99.2% respectively[14] Upcoming Unlocks - In the second week of February, three new stocks are expected to unlock, with a total unlock scale of 254 million yuan, maintaining low levels[35]

Core Viewpoint - Zhendemedical has experienced a consecutive two-day trading limit increase, indicating strong market interest and potential investor confidence [1] Group 1: Stock Performance - Zhendemedical's stock reached a trading limit at 9:58 AM with a transaction volume of 453 million yuan and a turnover rate of 1.96% [1] Group 2: Corporate Governance and Strategy - The company is optimizing its corporate governance structure by introducing a stock ownership plan for core employees and establishing a mechanism for repurchasing and canceling unblocked shares, which is expected to enhance team stability [1] - Zhendemedical is also engaging in hedging activities to mitigate risks associated with raw material price fluctuations, ensuring stable production costs [1] Group 3: Industry Context - Other companies within the pharmaceutical sector are showing positive performance due to improved governance and stable business operations, contributing to a sector-wide synergy effect [1]

Core Viewpoint - Aikang Medical (01789) shares rose over 5%, currently up 5.29% at HKD 6.17, with a trading volume of HKD 20.71 million [1] Group 1: Company Developments - Aikang Medical announced on February 9 that it has secured six bids from December 2024 to January 2026, involving its self-developed K3 robot system, K3+ robot system, Visual Treatment Solution, and a digital orthopedic full-process solution [1] - The total bid value for four of the projects amounts to RMB 23.54 million, while the remaining two bids have not yet disclosed their values [1] - Among the six projects, one bid for Shandong Provincial Hospital is valued at RMB 4.46 million, expected to recognize revenue in 2026, with two bids awarded this year from Zhejiang University School of Medicine First Affiliated Hospital and a hospital in Shandong [1]

Core Viewpoint - Aikang Medical (01789) has seen a stock price increase of over 5%, currently trading at 6.17 HKD with a transaction volume of 20.71 million HKD, following the announcement of six successful bids for various medical systems and solutions [1] Group 1: Company Developments - Aikang Medical announced on February 9 that it has secured six bids from December 2024 to January 2026, which include its self-developed K3 robot system, K3+ robot system, Visual Treatment Solution, and a comprehensive digital orthopedic solution [1] - The total bid amount for four of these projects is 23.54 million RMB, while the amounts for the remaining two bids have yet to be disclosed [1] - One of the notable projects includes a bid for Shandong Provincial Hospital, valued at 4.46 million RMB, expected to recognize revenue in 2026 [1] Group 2: Market Response - Following the announcement, Aikang Medical's stock price rose by 5.29%, indicating positive market sentiment towards the company's recent achievements [1] - The trading volume reached 20.71 million HKD, reflecting increased investor interest in the company's future prospects [1]

【中信证券海外策略】 12026年1月29日至2月4日EPFR跟踪的全球资金整体流入发达市场及新兴市场分别为251.65/88.27亿美元。 全球主动资金流入中国市场约7.03亿美元。 全球主动资金流入中国市场约7.03亿美元。 分不同区域主动资金情况看，本周欧洲区域资金流入规模最大，为0.7亿美元。 分行业看，本周中国资产各板块均呈流入趋势，其中信息技术、金融和可选消费板块流入规模最大，分别为 0.94/0.79/0.63亿美元。 2我们测算，2026年1月26日至1月30日，港股通/外资中介/内资中介分别净流入18/113/-118亿港元。 南向资金边际流入游戏、电池、医疗器械等板块；而外资增持黄金、半导体、造纸等板块。 互联网、保险、地产、多元金融、建材获南向及外资的共同青睐。 分不同区域主动资金情况看，本周欧洲区域资金流入规模最大，为0.7亿美元。 分行业看，本周中国资产各板块均呈流入趋势，其中信息技术、金融和可选消费板块流入规模最大，分别为 0.94/0.79/0 【中信证券海外策略】 12026年1月29日至2月4日EPFR跟踪的全球资金整体流入发达市场及新兴市场分别为251.65/88.27亿美 ...

Core Viewpoint - The company Huatai Medical (688617) announced a share buyback plan to enhance investor confidence and establish a long-term incentive mechanism, with a total buyback amount between 150 million and 200 million yuan, at a maximum price of 315 yuan per share [1] Group 1: Buyback Plan - The buyback will be conducted through centralized bidding and is expected to occur within 10 months from the board's approval [1] - The estimated number of shares to be repurchased ranges from 476,200 to 634,900, representing 0.34% to 0.45% of the company's total share capital [1] - The company stated that the buyback will not significantly impact its daily operations, finances, research and development, or future growth [1] Group 2: Company Performance - Huatai Medical specializes in the research, production, and sales of electrophysiological and interventional medical devices, focusing on coronary pathways and cardiac electrophysiology [1] - For the first three quarters of 2025, the company reported total operating revenue of 1.867 billion yuan, a year-on-year increase of 22.47%, and a net profit attributable to shareholders of 623 million yuan, up 18.02% year-on-year [1]

Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and has reported its financial performance, indicating growth in revenue and net profit [1][2]. - As of February 9, Weigao Blood Purification's stock price increased by 0.47%, with a trading volume of 36.10 million yuan. The financing buy-in amount was 5.05 million yuan, while the financing repayment was 7.37 million yuan, resulting in a net financing buy of -2.32 million yuan [1]. - The total balance of margin trading for Weigao Blood Purification as of February 9 is 120 million yuan, which accounts for 7.56% of its circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2]. - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].